Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug;27(4):790-801.
doi: 10.1111/1744-9987.13974. Epub 2023 Feb 16.

Immunoadsorption to treat patients with severe post-COVID syndrome

Benjamin Giszas  1 , Philipp A Reuken  1 , Katrin Katzer  1 , Michael Kiehntopf  2 , Diana Schmerler  2 , Silke Rummler  3 , Andreas Stallmach  1 , Anne Klink  3
Affiliations
Clinical Trial

Immunoadsorption to treat patients with severe post-COVID syndrome

Benjamin Giszas et al. Ther Apher Dial. 2023 Aug.

Abstract

Introduction: Following SARS-CoV-2-infection up to 21% of patients will develop post-COVID-syndrome. Autoantibodies (AAbs) targeting neuronal-ß-adrenergic and muscarinic receptors may provide crucial contributions to the pathophysiology of this condition. Immunoadsorption (IA) has been identified as an effective means of removing AAbs and has resulted in clinical improvements of other autoantibody-associated diseases.

Methods: We determined AAb-levels (anti-ß1/ß2 and anti-M3/M4 receptor) in 178 patients diagnosed with post-COVID-syndrome and described the clinical courses of two patients with elevated AAb-levels that underwent IA-treatment.

Results: AAbs were detected in 57% (101/178) of patients diagnosed with post-COVID-syndrome. Substantial reductions in AAb-levels and clinical remission were achieved in one of two patients who was treated with IA. However, this patient relapsed within 6 weeks with a concomitant increase in AAb-levels.

Conclusion: Collectively, AAbs may play a pathophysiologic role in post-COVID and their removal provide transient benefits in some patients. However, these findings should be further investigated in randomized-controlled-trials.

Keywords: autoantibodies; immunoadsorption; muscarinic receptors; post-COVID syndrome; ß-adrenergic receptors.

PubMed Disclaimer

References

REFERENCES

    1. Giszas B, Trommer S, Schüßler N, Rodewald A, Besteher B, Bleidorn J, et al. Post-COVID-19 condition is not only a question of persistent symptoms: structured screening including health-related quality of life reveals two separate clusters of post-COVID. Infection. 2022;22:1-13.
    1. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.
    1. Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016;52:32-9.
    1. Szewczykowski C, Mardin C, Lucio M, Wallukat G, Hoffmanns J, Schröder T, et al. Long COVID: Association of Functional Autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation. Int J Mol Sci. 2022;23(13):7209.
    1. Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.

Publication types

LinkOut - more resources